Results 1 to 10 of about 16,038 (157)

Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia

Molecular Therapy - Oncolytics, 2023
CD33 and CD123 are expressed on the surface of human acute myeloid leukemia blasts and other noncancerous tissues such as hematopoietic stem cells. On-target off-tumor toxicities may limit chimeric antigen receptor T cell therapies that target both CD33 ...
Marco L Davila, Justin C Boucher
exaly   +4 more sources

Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia

Molecular Therapy - Oncolytics, 2020
Chimeric antigen receptor T cells (CAR-T) targeting CD19 or B cell maturation antigen (BCMA) are highly effective against B cell malignancies. However, application of CAR-T to less differentially expressed targets remains a challenge due to lack of tumor-
Anja Feldmann, Malte von Bonin, Marc Cartellieri   +2 more
exaly   +4 more sources

Prognostic implications of CD123 in pediatric B-cell acute lymphoblastic leukemia: a single-center retrospective analysis [PDF]

Frontiers in Pediatrics
IntroductionAcute lymphoblastic leukemia (ALL) is the most common pediatric hematologic malignancy, with the majority of cases being of B-cell origin. While many patients respond favorably to therapy, a subset experiences early relapse or poor outcomes ...
Zheng Li, Qinfa Chen, Zhiyong Zhou, Fei He   +3 more
doaj   +2 more sources

Prognostic impact of CD123 overexpression on the outcome of pediatric acute myeloid leukemia [PDF]

Frontiers in Oncology
Background and aimsDespite advances in acute myeloid leukemia (AML) therapy, outcomes remain poor. CD123 overexpression influences proliferation and enhanced survival of leukemic cells. Its impact on the outcome is still debatable.
Mona Mohammed, Iman Sidhom, Nahla El-Sharkawy, Mahmoud Hammad, Maram Salama, Sonia Soliman, Dina Yassin, Sherine Salem, Nayera Hamdy, Amr Elnashar, Sherif Abouelnaga, Sonia Ahmed, Ahmed Elhemaly, Alaa Elhaddad   +13 more
doaj   +2 more sources

Prognostic value of CD25/CD123 pattern of expression in acute myeloid leukemia patients with normal cytogenetic

Leukemia Research Reports, 2020
This study was designed to assess the significance of interleukin-2 receptor (CD25) and inteleukin-3 receptor (CD123) expression in cytogenetically normal acute myeloid leukemia (CN-AML) patients.
Salah Aref, Mohamed Sabry
exaly   +3 more sources

Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models

Frontiers in Immunology, 2022
Immunotherapy with T-cells expressing bispecific T-cell engagers (ENG T-cells) is a promising approach to improve the outcomes for patients with recurrent/refractory acute myeloid leukemia (AML).
Hong Mu-Mosley, Lauren Ostermann, Muharrem Muftuoglu, Abishek Vaidya, Challice L. Bonifant, Mireya Paulina Velasquez, Stephen Gottschalk, Michael Andreeff   +7 more
doaj   +2 more sources

Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape

Translational Oncology, 2023
Purpose: Acute myeloid leukemia (AML) is a highly heterogeneous neoplastic disease with a poor prognosis that relapses even after its treatment with chimeric antigen receptor (CAR)-T cells targeting a single antigen.
Danni Xie, Xin Jin, Rui Sun, Meng Zhang, Wenyi Lu, Xinping Cao, Ruiting Guo, Yi Zhang, Mingfeng Zhao   +8 more
doaj   +2 more sources

Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123

Nature Biotechnology, 2023
Leukemia cells resistant to CD123-targeted therapies are susceptible to a trifunctional NK cell engager. CD123, the alpha chain of the IL-3 receptor, is an attractive target for acute myeloid leukemia (AML) treatment.
L. Gauthier, A. Virone-Oddos, J. Beninga, Benjamín Rossi, C. Nicolazzi, Céline Amara, Audrey Blanchard-Alvarez, Nicolas Gourdin, Jacqueline Courta, A. Basset, M. Agnel, Franceline Guillot, Gwendoline Grondin, Hélène Bonnevaux, A. Bauchet, Ariane Morel, Y. Morel, M. Chiron, É. Vivier   +18 more
semanticscholar   +1 more source

Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 costimulation

Haematologica, 2022
The outcome of patients with acute myeloid leukemia remains poor, and immunotherapy has the potential to improve this. T cells expressing chimeric antigen receptors or bispecific T-cell engagers targeting CD123 are actively being explored in preclinical
Abishek Vaidya, Erin Doherty, Xiya Wu, Sujuan Huang, Nikhil Hebbar, Unmesha Thanekar, Challice L. Bonifant, Cheng Cheng, Stephen Gottschalk, M. Paulina Velasquez   +9 more
doaj   +1 more source

Increased expressions of CD123, CD63, CD203c, and Fc epsilon receptor I on blood leukocytes of allergic asthma

Frontiers in Molecular Biosciences, 2022
Background: Altered basophil identification markers have been discovered to associate with allergic asthma (AA) in recent years. However, little is known about the expression of basophil markers in blood granulocytes.Aim: To parallel test blood basophils
Hua Xie, Hua Xie, Liping Chen, Liping Chen, Huiyun Zhang, Junling Wang, Yanyan Zang, Mengmeng Zhan, Fangqiu Gu, Shunlan Wang, Shaoheng He, Shaoheng He   +11 more
doaj   +1 more source